Lanreotide

Mechanism

A long-acting injectable that mimics the hormone somatostatin to suppress growth hormone and other hormones. Used to treat acromegaly (excess growth hormone) and certain neuroendocrine tumors. Given as a deep subcutaneous injection once every 4 weeks — the drug forms a depot under the skin that slowly releases over the month.

Effects

**Endocrine — Somatostatin System (Tier 1 — Human Clinical):** Lanreotide is a synthetic octapeptide somatostatin analog with preferential binding to somatostatin receptor subtypes 2 (SSTR2) and 5 (SSTR5). It inhibits growth hormone (GH), IGF-1, insulin, glucagon, and various gut peptides. In acromegaly, lanreotide normalizes GH (<2.5 ng/mL) and IGF-1 in approximately 50–70% of patients. **Gastrointestinal (Tier 1 — Human Clinical):** Suppresses GI hormone secretion (gastrin, VIP, secretin, motilin, CCK). Slows GI motility, reduces splanchnic blood flow, and decreases pancreatic exocrine secretion. Used for symptomatic control of neuroendocrine tumor-related diarrhea and flushing (carcinoid syndrome). **Tumor Growth Inhibition (Tier 1 — Human Clinical):** The CLARINET trial demonstrated lanreotide significantly prolongs progression-free survival in patients with metastatic enteropancreatic neuroendocrine tumors (NETs), regardless of functional status. Anti-proliferative effect mediated through SSTR2 activation of phosphotyrosine phosphatases and inhibition of MAPK/PI3K pathways. **Hepatobiliary (Tier 1 — Human Clinical, Side Effect):** Somatostatin analogs reduce gallbladder contractility and bile flow, leading to gallstone formation (cholelithiasis) in 15–30% of patients on long-term therapy. This is a class effect of all somatostatin analogs. **Metabolic (Tier 1 — Human Clinical):** Suppresses insulin secretion, which can worsen glucose homeostasis. Hyperglycemia or worsening of pre-existing diabetes reported in 5–15% of patients. Less pronounced than with pasireotide but still clinically relevant.

Practitioner Guide

**APPROVED INDICATIONS:** • Acromegaly (when surgery and/or radiation inadequate). • Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) — anti-proliferative and symptom control. • Carcinoid syndrome — symptom management (diarrhea, flushing). **DOSING:** • Somatuline Depot: 60, 90, or 120 mg deep subcutaneous injection every 28 days. • Acromegaly: Start 90 mg every 28 days. Adjust based on GH/IGF-1 levels after 3 months. • NETs: 120 mg every 28 days (CLARINET trial dose). • Injection technique: Deep subcutaneous in the superior outer quadrant of the buttock. The pre-filled syringe has a thick-gauge needle — inject firmly and quickly. Alternate sides monthly. **GALLSTONE PREVENTION STRATEGIES (Deep Clinical Pearls):** • Baseline gallbladder ultrasound before starting somatostatin analog therapy. • Ursodeoxycholic acid (UDCA) 300 mg twice daily: Prophylactic UDCA reduces gallstone incidence during somatostatin analog therapy. Many endocrinologists prescribe this routinely for patients on long-term lanreotide. • Dietary: Encourage adequate fat intake at meals (this promotes gallbladder contraction and bile flow, counteracting the stasis caused by somatostatin analogs). A completely low-fat diet paradoxically INCREASES gallstone risk. • Monitoring: Annual gallbladder ultrasound during treatment. Many patients develop biliary sludge that may or may not progress to symptomatic stones. • Clinical pearl: If gallstones are discovered during treatment but are asymptomatic, continue lanreotide with UDCA. Do not reflexively discontinue effective cancer/acromegaly treatment for asymptomatic cholelithiasis. Cholecystectomy if symptomatic. **MANAGING HYPERGLYCEMIA:** • Monitor fasting glucose and HbA1c at baseline, 3 months, and every 6 months during treatment. • Lanreotide-associated hyperglycemia is generally mild compared to pasireotide. Most patients manage with oral hypoglycemics (metformin first-line). • In diabetic patients: Expect modest worsening of glycemic control. Pre-emptive dose adjustment of diabetes medications may be warranted. **LAR INJECTION TECHNIQUE:** • Lanreotide is a thick, viscous gel in a pre-filled syringe — injection technique matters: - Remove from refrigerator 30 minutes before injection (room temperature reduces viscosity). - Use the entire needle length — inject deeply into subcutaneous tissue. - Inject with steady, continuous pressure over 20–30 seconds. Do not aspirate. - Do NOT massage the injection site afterward — this disrupts the depot formation. - If the injection is too superficial, a painful nodule forms. Depth is key. **INTERACTION WITH GH PEPTIDE COMMUNITY:** • Some individuals using GH secretagogues (ipamorelin, CJC-1295, etc.) or exogenous GH encounter unwanted side effects: excessive water retention, joint pain, carpal tunnel, or acromegalic features from supraphysiological GH/IGF-1 levels. • In the peptide community, low-dose octreotide (see octreotide entry) is sometimes used to "brake" GH effects. Lanreotide is NOT typically used for this purpose due to its long-acting depot formulation — it provides weeks of suppression, making dose titration impossible. • Clinical pearl: If a patient on GH peptides develops concerning IGF-1 elevations or symptoms, the correct approach is to REDUCE GH peptide dosing, not add a somatostatin analog. Somatostatin analogs are pharmaceutical-grade medications with significant side effects (gallstones, hyperglycemia, GI disturbance) that are not appropriate for managing elective GH peptide use.

Evidence

• Lanreotide in metastatic enteropancreatic neuroendocrine tumors

  Caplin ME et al. (2014) — N Engl J Med — PMID: 25014687

  In the CLARINET trial, lanreotide 120 mg every 28 days significantly prolonged progression-free survival versus placebo in metastatic grade 1-2 enteropancreatic neuroendocrine tumors; estimated 24-month PFS was 65.1% with lanreotide vs 33.0% with placebo, hazard ratio 0.47.

  strong

Research Summary

**Tier 1 (Human Clinical Evidence):** • Acromegaly: Multiple Phase III trials. Normalizes GH/IGF-1 in 50–70% as monotherapy. Non-inferior to octreotide LAR. • CLARINET trial (Lancet, 2014): Landmark Phase III RCT. Lanreotide 120 mg monthly significantly prolonged PFS vs placebo in GEP-NETs (median PFS not reached vs 18 months). Led to FDA approval for NETs. • Carcinoid syndrome: Reduces diarrhea episodes by 50–70% and flushing frequency significantly. • Safety: Gallstones (15–30%), GI disturbance (diarrhea, abdominal pain in 20–30%), injection site reactions (5–10%), hyperglycemia (5–15%). **Tier 2 (Strong Preclinical + Mechanistic):** • SSTR2/SSTR5 binding profile well-characterized. Anti-proliferative mechanism through phosphotyrosine phosphatase activation is established. • Pharmacokinetic profile of the depot formulation provides stable drug levels over 28 days. **Tier 3 (Emerging / Theoretical):** • Combination with targeted therapies (everolimus, sunitinib) for NETs is under investigation. • Potential role in polycystic liver/kidney disease (suppression of cyst growth) — early clinical data is encouraging.